Metropolitan Life Insurance Company (MetLife)’s Ventyx Biosciences VTYX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio VTYX Stock Details VTYX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,579	Closed	-$14.2K	–	2072
2024 Q1	$14.2K	Buy	+2,579	New	+$11.8K	﹤0.01%	2016
2023 Q4	–	Sell	-2,755	Closed	-$95.7K	–	2391
2023 Q3	$95.7K	Buy	2,755 +181	+7%	+$6.26K	0.01%	1044
2023 Q2	$84.4K	Buy	2,574 +1,242	+93%	+$42.8K	﹤0.01%	1111
2023 Q1	$44.6K	Sell	1,332 -180	-12%	-$7K	﹤0.01%	1449
2022 Q4	$49.6K	Hold	1,512	–	–	﹤0.01%	1482
2022 Q3	$52.8K	Hold	1,512	–	–	﹤0.01%	1429
2022 Q2	$18.5K	Buy	+1,512	New	+$22.6K	﹤0.01%	2077

Other funds holding VTYX

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s VTYX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Ventyx Biosciences (VTYX) in Q2 2024, closing a stake of 2,579 shares — an estimated $14.2K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in VTYX in Q2 2022 and held it in 7 quarters. The position peaked at $95.7K in Q3 2023. 117 funds tracked by Wall St. Rank hold VTYX as of Q2 2024.

Metropolitan Life Insurance Company (MetLife) reported no remaining Ventyx Biosciences position as of Q2 2024 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 2,579 Ventyx Biosciences shares in Q2 2024, an estimated $14.2K.
Metropolitan Life Insurance Company (MetLife) first reported a position in Ventyx Biosciences in Q2 2022 and held it in 7 quarters.
Metropolitan Life Insurance Company (MetLife)'s Ventyx Biosciences position peaked at $95.7K in Q3 2023.
117 funds tracked by Wall St. Rank held Ventyx Biosciences as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.